⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
globenewswire.com
REGN
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
globenewswire.com
OCUL
REGN
MRK
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
COLL
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica
globenewswire.com
TMO
AMGN
PFE
BMY
GILD
REGN
AZN
LLY
MRK
GSK
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
businesswire.com
REGN
MaaT Pharma annonce la randomisation du premier patient dans IMMUNOLIFE, essai Phase 2 promu par Gustave Roussy évaluant le rôle du microbiote pour contourner la résistance aux ICI chez des patients CPNPC avancé avec dysbiose liée aux antibiotiques
businesswire.com
REGN
Think Bioscience Raises $55M in Oversubscribed Series A
prnewswire.com
REGN
JHG
BrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and Innovation
globenewswire.com
SNY
REGN
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
globenewswire.com
SNY
REGN